Transcript

Adding Benign Disease Is A Referral Decision, Not An Equipment Decision · Medsolve Dynamics

Yoel Bakas: The fastest service line you can add to an oncology program in 2026 does not require additional capital. Many programs already have extra LINAC capacity. Think of open slots on a Tuesday afternoon, early morning slots before your treatment day begins. What they don't necessarily have is a referral pathway. Of course, what I'm talking about is benign disease treatments. Think of orthopedic issues, plantar fasciitis, knee pain, osteoarthritis, dupuytren's etc. The capital case is already made and paid. Reimbursement is favorable. and the clinical evidence guidelines exist both through AAPM and ASTRO. Support exists from organizations around the world. But none of that matters if the orthopedist down the street doesn't know where to send that patient. Adding benign disease is not an equipment decision, it's a referral decision. The programs that have made benign disease work have walked their local orthopedic department, the local dermatology programs, the local pain management physicians through exactly what this process looks like. A little bit of marketing, a little bit of networking, and a little bit of planning goes a long way. Capital is already in your center, but your volume is in the community. The pathway between those two is where the work exists.